title: Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
abstract: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, dosage and administration, and cost of olanzapine are reviewed. Olanzapine is a serotonin-dopamine-receptor antagonist indicated for use in the treatment of schizophrenia and other psychotic disorders. The affinity of olanzapine for neuroreceptors is similar to that of clozapine. The drug is well absorbed from the GI tract; food has no effect. Olanzapine is more effective than placebo and equal to haloperidol in reducing psychotic symptoms on two rating scales. However, unlike typical dopamine-receptor antagonists used for antipsychotic therapy, olanzapine is more effective in reducing the negative symptoms of schizophrenia. The most frequent adverse drug reactions (ADRs) associated with olanzapine are somnolence, agitation, insomnia, and headache. Constipation and dry mouth occur as dose-dependent ADRs. Unlike clozapine, olanzapine does not cause agranulocytosis. No cases of tardive dyskinesia or neuroleptic malignant syndrome have been reported. Olanzapine has been associated with slight increases in hepatic transaminases. More study is needed to determine whether olanzapine interacts significantly with other drugs. The recommended starting dosage is 5-10 mg orally once daily. Efficacy beyond six weeks has not been evaluated; patients treated for longer than six weeks should be periodically reassessed. Olanzapine costs about 10 times more than typical antipsychotics because a generic version is not available; however, olanzapine costs less than clozapine therapy and may cost less than haloperidol in terms of total health care costs. Olanzapine offers an effective alternative for treating schizophrenia and has a favorable adverse-effect profile.
authors.affiliation: College of Pharmacy, University of Iowa, Iowa City 52242-0123, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Bever
authors.forename: P J
authors.initials: PJ
authors.lastname: Perry
mesh_terms: D014150:Antipsychotic Agents / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D018492:Dopamine Antagonists / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000191:economics; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D012702:Serotonin Antagonists / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D012702:Serotonin Antagonists; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine